NeuLogiq platform earned high marks from ALS and FTD patients using it at home, addressing a gap left by motor-only rating scales.
The tool doctors have relied on for years to track ALS was built to measure grip strength and swallowing, not memory or mood. That gap is what Cumulus Neuroscience is trying to close, and its first real test of whether patients would even tolerate the fix just came back.
The Belfast digital health company announced the publication of final results from its CNS-102 study in Scientific Reports. The trial put an at-home headset called the NeuLogiq Platform in front of people with ALS and frontotemporal dementia, or FTD, over eight months [1]. The takeaway: even patients with serious motor and speech impairment could use it, and most of them liked it.
ALS is known for attacking the nerves that control movement – the ability to walk, speak, eat, breathe. Less widely known is that a meaningful share of ALS patients also develop cognitive and behavioral changes, sometimes crossing into full frontotemporal dementia. Doctors increasingly treat the two as one spectrum disorder rather than separate conditions.
The problem is the field’s standard measurement, a scale called the ALSFRS-R, only tracks motor decline. It was never built to catch what’s happening cognitively. Researchers have been flying half-blind on that front for years.
Testing it where patients actually live
NeuLogiq pairs a 16-channel wireless EEG headset with a tablet running short, game-like cognitive tasks covering memory, language and decision-making. In CNS-102, 28 participants – 11 with ALS, 7 with FTD, 10 healthy controls – used the setup at home every two weeks for eight months, alongside standard clinic visits at the start, middle and end.
The result caught even the researchers off guard. Despite the physical toll of ALS, that group rated the platform easier to use than either the FTD group or the healthy controls did. Eighty-two percent of ALS participants called it easy to use; 75% walked away with a positive or very positive overall impression. And the sessions people did complete produced clean data – 92% completeness.
“This peer-reviewed publication is an important milestone for the NeuLogiq Platform and for the wider effort to bring richer measurements to ALS–FTD,” said Dr Brian Murphy, Founder and Chief Scientific Officer of Cumulus.
Murphy emphasized that the scientific significance of their gamified, self-administered home assessments lies in their ability to distinguish between ALS, FTD and control groups at baseline with effect sizes comparable to a research-grade, clinician-administered battery. He noted that individuals living with these conditions completed a high volume of sessions and reported positive experiences in their own words.
Cumulus’ founder concluded that this blend of objective, multimodal data alongside genuine patient acceptability provides pharma partners with the essential foundation needed to design more sensitive, patient-centered neurodegenerative disease trials.
The part the clinic missed
The more interesting thread is in the longitudinal data. Over eight months, home testing picked up early signs of change in the ALS group’s speech fluency and facial-expression recognition – changes the in-clinic testing didn’t detect over that same window. It’s a small sample, and the researchers are careful to call it exploratory rather than definitive. But it points to something worth taking seriously: testing every two weeks at home may catch shifts that testing three times a year in a clinic simply walks past.
“Cognitive and behavioural change is a defining feature of ALS–FTSD, yet most of our standard clinical tools – including the ALSFRS-R – were never designed to capture it,” said Professor Orla Hardiman, MD, Head of the Academic Unit of Neurology at Trinity College Dublin and Principal Investigator of CNS-102. “What CNS-102 shows is that a home-based platform combining EEG with multi-domain cognitive assessment can be tolerated, and even welcomed, by people living with significant motor and cognitive impairment, and that it produces high-quality data that distinguish patient groups as well as a full in-clinic battery.”
Adding years to a life doesn’t count for much if the years gained arrive with cognitive decline nobody caught in time to act on. What NeuLogiq points toward is neurodegenerative disease tracked continuously instead of glimpsed a few times a year, a much earlier warning system for drug developers, and eventually for patients themselves. That kind of fine-grained monitoring is becoming one of the more consequential frontiers in longevity research, not because it’s a new drug, but because it’s a better way of knowing whether the brain is actually holding steady.
